Free shipping on all orders over $ 500

Cediranib

Cat. No. M1696

Cediranib Structure

Synonym: AZD2171

Size Price Availability Quantity
10mg USD 100 In stock
50mg USD 250 In stock
Bulk Inquiry?

Quality Control
Biological Activity

Cediranib (AZD2171) inhibited VEGFR2 and KDR phosphorylation with IC50s of 0.4 and 0.5 nM, respectively. Cediranib significantly increased survival of mice wth glioblastoma by decreasing tumor vessel permeability, normalizing perivascular cell coverage, and thinning of the basement membrane, thus controlling edema. Cediranib demonstrated potent antitumor and antiangiogenic efficacy in the murine renal cell carcinoma model.

Protocol
Cell Experiment
Cell lines HUVEC cells line
Preparation method Inhibition of growth factor–mediated cellular proliferation.
HUVEC proliferation in the presence and absence of growth factors was evaluated following a 4-day incubation by 3H-thymidine incorporation, as described previously. Proliferation of MG63 osteosarcoma cells was induced by PDGF-AA, which selectively activates PDGFR-α homodimer signaling. Cells were cultured in DMEM without phenol red (Sigma-Aldrich) containing 1% charcoal stripped FCS, 2 mmol/L glutamine, and 1% nonessential amino acids (Invitrogen, Paisley, United Kingdom) for 24 hours. AZD2171 or vehicle was added with PDGF-AA ligand (50 ng/mL; Sigma-Aldrich) and plates reincubated for 72 hours. Cellular proliferation was determined using a bromodeoxyuridine ELISA (Roche Diagnostics Ltd., Lewes, United Kingdom).
Concentrations 0~10 μ M
Incubation time 72 h
Animal Experiment
Animal models female Alderley Park mice or rat bearing human tumor xenografts model
Formulation suspended in 1% (w/v) aqueous polysorbate 80 (polyoxyethylene; sorbitan mono-oleate in deionized water)(mice) / 0.5% (w/v) hydroxypropyl methylcellulose solution containing 0.1% (w/v) aqueous polysorbate 80(rat)
Dosages 0.75-6 mg/kg
Administration orally
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 450.51
Formula C25H27FN4O3
CAS Number 288383-20-0
Purity >99%
Solubility DMSO
Storage at -20°C
References

Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II).
Hoff et al. J Clin Oncol. 2012 Sep 10. PMID: 22965965.

Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III).
Schmoll et al. J Clin Oncol. 2012 Sep 10. PMID: 22965961.

Advanced Solid Tumors Treated with Cediranib: Comparison of Dynamic Contrast-enhanced MR Imaging and CT as Markers of Vascular Activity.
Messiou et al. Radiology. 2012 Aug 13. PMID: 22891356.

Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium.
Campbell et al. Lung Cancer. 2012 Jul 23. PMID: 22831987.

Cediranib: a VEGF receptor tyrosine kinase inhibitor.
Sahade et al. Future Oncol. 2012 Jul;8(7):775-81. PMID: 22830398.

Response of HT29 colorectal xenograft model to cediranib assessed with (18) F-fluoromisonidazole positron emission tomography, dynamic contrast-enhanced and diffusion-weighted MRI.
Bokacheva et al. NMR Biomed. 2012 Jul 8. PMID: 22777834.

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
Wedge SR, et al. Cancer Res. 2005 May 15;65(10):4389-400. PMID: 15899831.

Related VEGFR/PDGFR Products
Regorafenib HCl

Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively.

Pazopanib HCl (GW786034 )

Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Dovitinib (TKI-258) Dilactic Acid

Dovitinib Dilactic acid (TKI258 Dilactic acid) is the Dilactic acid of Dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM.

Toceranib

Toceranib(SU 11654; PHA 291639) is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ.

Nintedanib (BIBF 1120)

Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM in cell-free assays. Phase 3.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: Cediranib, AZD2171 supplier, VEGFR/PDGFR, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.